Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications

Implication of ncRNAs in cellular signaling pathways related to cancer immune resistance. NcRNAs can affect the efficacy of immunotherapy through modulation of cancer cell ferroptosis. miR-21-3p accelerates IFN-γ-mediated ferroptosis by downregulating TXNRD1 to impel lipid peroxidation. NEAT1 increases MIOX expression by sponging miR-362-3p. This event enhances ROS production and decreases the intracellular levels of NADPH and GSH, eventually leading to cancer cell ferroptosis. Moreover, NEAT1 reinforces the anticancer potency of ferroptosis activators erastin and RSL3. LINC01085 inhibits the phosphorylation of TBK1 by abating its interaction with GSK3β. Accordingly, LINC01085 blocks the activation of the STING/MAVS/IRF3 signaling pathway, resulting in downregulation of NF-κB and PD-L1 and decreased production of type I/III IFNs. LINC01085 can act in synergy with anti-PD-L1 treatment. PD-L1, programmed cell death-ligand 1; PD-1, programmed cell death protein-1; IFN-γ, interferon-γ; MAVS, mitochondrial antiviral signaling protein; STING, stimulator of interferon genes; GSK3β, glycogen synthase kinase 3β; TKB1, TANK-binding kinase 1; IRF3, interferon regulatory factor 3; NF-κB, nuclear factor-κB; TXNRD1, thioredoxin reductase 1; RSL3, RAS-selective lethal 3; MIOX, myo-inositol oxygenase; GSH, glutathione; NAPDH, nicotinamide adenine dinucleotide phosphate; GPX4, glutathione peroxidase 4; GSR, glutathione reductase; GSSG, oxidized glutathione; ROS, reactive oxygen species.
Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications

Publication

Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications. (2023) Man Wang, et al. Front Immunol. 2023;14:1268745. Figure: F3.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates IRF3 IRF3 ncbigene_symbol IRF3 3661
Homo sapiens Primates STING STING ncbigene_synonym STING1 340061
Homo sapiens Primates MAVS MAVS ncbigene_symbol MAVS 57506
Homo sapiens Primates GSK3B GSK3B ncbigene_symbol GSK3B 2932
Homo sapiens Primates LINC01085 LINC01085 ncbigene_symbol LINC01085 152742
Homo sapiens Primates TBK1 TBK1 ncbigene_symbol TBK1 29110
Homo sapiens Primates NF-KB NF-KB ncbigene_synonym NFKB1 4790
Homo sapiens Primates CD8+ CD8 ncbigene_synonym CD8A 925
Homo sapiens Primates CD8+ CD8 famplex_relations CD8B 926
Homo sapiens Primates PD-1 PD-1 ncbigene_synonym PDCD1 5133
Homo sapiens Primates PD-1 PD-1 ncbigene_synonym RPL17 6139
Homo sapiens Primates PD-1 PD-1 ncbigene_synonym RPL17-C18orf32 100526842
Homo sapiens Primates PD-L1 PD-L1 ncbigene_synonym CD274 29126
Homo sapiens Primates NEAT1 NEAT1 ncbigene_symbol NEAT1 283131
Homo sapiens Primates MIOX MIOX ncbigene_symbol MIOX 55586
Homo sapiens Primates GPX4 GPX4 ncbigene_symbol GPX4 2879
Homo sapiens Primates GSR GSR ncbigene_symbol GSR 2936

Chemical mentions

Word Match MeSH Name ChEBI
Glutamate NA
Cystine Cystine mesh:D003553 cystine chebi:17376
Cysteine Cysteine mesh:D003545 cysteine chebi:15356
GSSG Glutathione Disulfide mesh:D019803 glutathione disulfide chebi:17858
GSH NAPDH Glutathione mesh:D005978 glutathione chebi:16856

Disease mentions

Word Match MeSH Name DOID